Mr. Stea has served on our board of directors since June 2015. From September 2016 to January 2018, Mr. Stea held a consulting role to assist La Jolla Pharmaceuticals in preparing for the commercialization of their first drug, Angiotensin II. Prior to this, Mr. Stea served as Senior Vice President of Commercial Operations for Cubist from 2009 to February 2015, leading all commercial operations, including the launch and sales of Cubicin, Zerbaxa and Sivextro. Prior to this, Mr. Stea served as Cubist’s Vice President, Sales and Marketing from 2007 to 2009. Having joined Cubist as an original member of the commercial organization, Mr. Stea served as Cubist’s Vice President of Sales from 2005 to 2007 and Executive Director of Sales from 2002 to 2005. Mr. Stea also served as a member of the Cubist Operating Committee from 2009 to February 2015, which was responsible for resource allocation, company strategy, risk management and compliance, among other responsibilities. Mr. Stea previously held leadership positions at Amgen from 1988 to 1997, where he was the first employee of its sales organization, responsible for the launch of Epogen and Neupogen.
Mr. Stea holds a Bachelor’s Degree in Business Administration from Temple University and completed the University of Michigan’s Executive Education program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology.